Extended-release niacin with laropiprant: a review on efficacy, clinical effectiveness and safety

Bibliography

• Soran H, Durrington P. Rosuvastatin: efficacy, safety and clinical effectiveness. Expert Opin Pharmacother 2008;9:2145-60
   PubMed Web of Science ®Google Scholar
• Shepherd J, Blauw G J, Murphy M B, Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30
   PubMed Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360:7-22
   PubMed Web of Science ®Google Scholar
• Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9
   PubMed Web of Science ®Google Scholar
• Bhatnagar D, Soran H, Durrington PN. Hypercholesterolaemia and its management. BMJ 2008;337:a993
   PubMed Web of Science ®Google Scholar
• Whayne TF Jr. High-density lipoprotein cholesterol: current perspective for clinicians. Angiology 2009;60:644-9
   PubMed Web of Science ®Google Scholar
• Chapman MJ, Redfern JS, McGovern ME, Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. Pharmacol Ther 2010;126:314-45
   PubMed Web of Science ®Google Scholar
• Downs JR, Clearfield M, Weis S, Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22
   PubMed Web of Science ®Google Scholar
• Gordon T, Castelli WP, Hjortland MC, High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med 1977;62:707-14
   PubMed Web of Science ®Google Scholar
• Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997;17:107-13
   PubMed Web of Science ®Google Scholar
• Sharrett AR, Ballantyne CM, Coady SA, Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2001;104:1108-13
   PubMed Web of Science ®Google Scholar
• Sacks FM. The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials. Am J Cardiol 2001;88:14N-8N
   PubMed Web of Science ®Google Scholar
• Barter P, Gotto AM, LaRosa JC, HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-10
   PubMed Web of Science ®Google Scholar
• Brookes L. Studies of raising HDL cholesterol: updates European Society of Cardiology (ESC) 2008 Congress. Medscape Cardiology, Medscape Conference Coverage 2009. Available from: http://www.medscape.com/viewarticle/585306
   Google Scholar
• Olsson A. Short and Long Term HDL-C Effects. In XIV International Symposium on Drugs Affecting LipidMetabolism; New York, USA; 2001
   Google Scholar
• Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-421
   PubMed Web of Science ®Google Scholar
• Carlson LA, Oro L, Ostman J. Effect of a single dose of nicotinic acid on plasma lipids in patients with hyperlipoproteinemia. Acta Med Scand 1968;183:457-65
   PubMedGoogle Scholar
• Parsons WB Jr, Achor RW, Berge KG, Changes in concentration of blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia: preliminary observations. Proc Staff Meet Mayo Clin 1956;31:377-90
   PubMed Web of Science ®Google Scholar
• Parsons WB Jr, Flinn JH. Reduction of serum cholesterol levels and beta-lipoprotein cholesterol levels by nicotinic acid. AMA Arch Intern Med 1959;103:783-90
   PubMedGoogle Scholar
• The Coronary Drug Project Research Group. Clofibrate and niacin in Coronary Heart disease. J Am Med Assoc 1975;231:360-81
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD, Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med 1990;323:1289-98
   PubMed Web of Science ®Google Scholar
• Brown BG, Zhao XQ, Chait A, Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Sullenberger LE, Lee HJ, Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-17
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Lee HJ, Sullenberger LE. The effect of 24 months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3. Curr Med Res Opin 2006;22:2243-50
   PubMed Web of Science ®Google Scholar
• Taylor AJ, Villines TC, Stanek EJ, Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009;361:2113-22
   PubMed Web of Science ®Google Scholar
• Boden WE, Probstfield JL, Anderson T, Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67
   PubMed Web of Science ®Google Scholar
• Nomura H, Nielsen BW, Matsushima K. Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. Int Immunol 1993;5:1239-49
   PubMed Web of Science ®Google Scholar
• Tunaru S, Kero J, Schaub A, PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat Med 2003;9:352-5
   PubMed Web of Science ®Google Scholar
• Ganji SH, Tavintharan S, Zhu D, Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res 2004;45:1835-45
   PubMed Web of Science ®Google Scholar
• Lamon-Fava S, Diffenderfer MR, Barrett PH, Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. Arterioscler Thromb Vasc Biol 2008;28:1672-8
   PubMed Web of Science ®Google Scholar
• Watts GF, Chan DC. Of mice and men: blowing away the cobwebs from the mechanism of action of niacin on HDL metabolism. Arterioscler Thromb Vasc Biol 2008;28:1892-5
   PubMed Web of Science ®Google Scholar
• van der Hoorn JW, de Haan W, Berbee JF, Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden. CETP mice. Arterioscler Thromb Vasc Biol 2008;28:2016-22
   PubMed Web of Science ®Google Scholar
• Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol 1997;17:2020-8
   PubMed Web of Science ®Google Scholar
• Martinez LO, Jacquet S, Esteve JP, Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003;421:75-9
   PubMed Web of Science ®Google Scholar
• Rubic T, Trottmann M, Lorenz RL. Stimulation of CD36 and the key effector of reverse cholesterol transport ATP-binding cassette A1 in monocytoid cells by niacin. Biochem Pharmacol 2004;67:411-19
   PubMed Web of Science ®Google Scholar
• Choudhury RP, Lee JM, Greaves DR. Mechanisms of disease: macrophage-derived foam cells emerging as therapeutic targets in atherosclerosis. Nat Clin Pract Cardiovasc Med 2005;2:309-15
   PubMedGoogle Scholar
• Pandolfi PP, Sonati F, Rivi R, Targeted disruption of the housekeeping gene encoding glucose 6-phosphate dehydrogenase (G6PD): G6PD is dispensable for pentose synthesis but essential for defense against oxidative stress. EMBO J 1995;14:5209-15
   PubMed Web of Science ®Google Scholar
• Ito Y, Pagano PJ, Tornheim K, Oxidative stress increases glyceraldehyde-3-phosphate dehydrogenase mRNA levels in isolated rabbit aorta. Am J Physiol 1996;270:H81-7
   PubMed Web of Science ®Google Scholar
• Cao Z, Li Y. Chemical induction of cellular antioxidants affords marked protection against oxidative injury in vascular smooth muscle cells. Biochem Biophys Res Commun 2002;292:50-7
   PubMed Web of Science ®Google Scholar
• Jacobson EL, Jacobson MK. A biomarker for the assessment of niacin nutriture as a potential preventive factor in carcinogenesis. J Intern Med 1993;233:59-62
   PubMed Web of Science ®Google Scholar
• Ganji SH, Qin S, Zhang L, Niacin inhibits vascular oxidative stress, redox-sensitive genes, and monocyte adhesion to human aortic endothelial cells. Atherosclerosis 2009;202:68-75
   PubMed Web of Science ®Google Scholar
• Yan Q, Briehl M, Crowley CL, The NAD+ precursors, nicotinic acid and nicotinamide upregulate glyceraldehyde-3-phosphate dehydrogenase and glucose-6-phosphate dehydrogenase mRNA in Jurkat cells. Biochem Biophys Res Commun 1999;255:133-6
   PubMed Web of Science ®Google Scholar
• Ganji SH. Niacin inhibits LDL oxidation and redox-sensitive VCAM-1 and MCP-1 expression in human aortic endothelial cells [abstract]. Arterioscler Thromb Vasc Biol 2004;24:125
   Web of Science ®Google Scholar
• Digby JE, McNeill E, Dyar OJ, Anti-inflammatory effects of nicotinic acid in adipocytes demonstrated by suppression of fractalkine, RANTES, and MCP-1 and upregulation of adiponectin. Atherosclerosis 2010;209:89-95
   PubMed Web of Science ®Google Scholar
• Kuvin JT, Dave DM, Sliney KA, Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol 2006;98:743-5
   PubMed Web of Science ®Google Scholar
• Knopp RH, Ginsberg J, Albers JJ, Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. Metabolism 1985;34:642-50
   PubMed Web of Science ®Google Scholar
• Birjmohun RS, Hutten BA, Kastelein JJ, Increasing HDL cholesterol with extended-release nicotinic acid: from promise to practice. Neth J Med 2004;62:229-34
   PubMed Web of Science ®Google Scholar
• Kamal-Bahl SJ, Burke T, Watson D, Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 2007;99:530-4
   PubMed Web of Science ®Google Scholar
• Kamal-Bahl SJ, Burke TA, Watson DJ, Dosage, titration, and gaps in treatment with extended release niacin in clinical practice. Curr Med Res Opin 2008;24:1817-21
   PubMed Web of Science ®Google Scholar
• Maccubbin D, Koren MJ, Davidson M, Flushing profile of extended-release niacin/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease. Am J Cardiol 2009;104:74-81
   PubMed Web of Science ®Google Scholar
• Benyo Z, Gille A, Bennett CL, Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol Pharmacol 2006;70:1844-9
   PubMed Web of Science ®Google Scholar
• Benyo Z, Gille A, Kero J, GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing. J Clin Invest 2005;115:3634-40
   PubMed Web of Science ®Google Scholar
• Maciejewski-Lenoir D, Richman JG, Hakak Y, Langerhans cells release prostaglandin D2 in response to nicotinic acid. J Invest Dermatol 2006;126:2637-46
   PubMed Web of Science ®Google Scholar
• Sturino CF, O'Neill G, Lachance N, Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocy clopenta[b]indol-3-yl]-acetic acid (MK-0524). J Med Chem 2007;50:794-806
   PubMed Web of Science ®Google Scholar
• Yadav R, Kwok S, Ammori BJ, Safety and tolerability of extended-release niacin with laropiprant. Expert Opin Drug Saf 2012;11:151-9
   PubMed Web of Science ®Google Scholar
• Lai E, Wenning LA, Crumley TM, Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist. Clin Pharmacol Ther 2008;83:840-7
   PubMed Web of Science ®Google Scholar
• Lai E, Schwartz JI, Dallob A, Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects. Platelets 2010;21:191-8
   PubMed Web of Science ®Google Scholar
• MSD. Summary of product characteristics TREDAPTIVE 1000 mg/20 mg modified release tablets. 2011. Available from: http://www.medicines.org.uk/EMC/medicine/22227/SPC/TREDAPTIVE+1000+mg+20+mg+modified+release+tablets/
   Google Scholar
• Mrochek JE, Jolley RL, Young DS, Metabolic response of humans to ingestion of nicotinic acid and nicotinamide. Clin Chem 1976;22:1821-7
   PubMed Web of Science ®Google Scholar
• Cayen MN. Disposition, metabolism and pharmacokinetics of antihyperlipidemic agents in laboratory animals and man. Pharmacol Ther 1985;29:157-204
   PubMed Web of Science ®Google Scholar
• McKenney JM, Proctor JD, Harris S, A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 1994;271:672-7
   PubMed Web of Science ®Google Scholar
• Menon RM, Gonzalez MA, Adams MH, Effect of the rate of niacin administration on the plasma and urine pharmacokinetics of niacin and its metabolites. J Clin Pharmacol 2007;47:681-8
   PubMed Web of Science ®Google Scholar
• Knopp RH. Evaluating niacin in its various forms. Am J Cardiol 2000;86:51L-6L
   PubMed Web of Science ®Google Scholar
• Wang YH, Liu F, Luk JA, Pharmacokinetics of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, in patients with moderate hepatic impairment. J Clin Pharmacol 2011;51:406-12
   PubMed Web of Science ®Google Scholar
• Stroh M, Wenning L, Luo WL, Pharmacokinetics of laropiprant and glucuronide metabolite in patients with severe renal insufficiency. Am J Ther 2009;16:379-84
   PubMed Web of Science ®Google Scholar
• Dallob A, Luo WL, Luk JM, The effects of laropiprant, a selective prostaglandin D(2) receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin. Platelets 2011;22:495-503
   PubMed Web of Science ®Google Scholar
• Schwartz JI, Liu F, Stroh M, Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin. Am J Ther 2009;16:215-23
   PubMed Web of Science ®Google Scholar
• Morgan JM, Capuzzi DM, Guyton JR, Treatment effect of Niaspan, a controlled-release niacin, in patients with hypercholesterolemia: a placebo-controlled Trial. J Cardiovasc Pharmacol Ther 1996;1:195-202
   PubMedGoogle Scholar
• Knopp RH, Alagona P, Davidson M, Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. Metabolism 1998;47:1097-104
   PubMed Web of Science ®Google Scholar
• Goldberg A, Alagona P Jr, Capuzzi DM, Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 2000;85:1100-5
   PubMed Web of Science ®Google Scholar
• Insull W Jr, McGovern ME, Schrott H, Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. Arch Intern Med 2004;164:1121-7
   PubMed Web of Science ®Google Scholar
• Hunninghake DB, McGovern ME, Koren M, A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. Clin Cardiol 2003;26:112-18
   PubMed Web of Science ®Google Scholar
• Capuzzi DM, Guyton JR, Morgan JM, Efficacy and safety of an extended-release niacin (Niaspan): a long-term study. Am J Cardiol 1998;82:74U-81U. discussion 5U-6U
   PubMed Web of Science ®Google Scholar
• Insull W Jr, Toth PP, Superko HR, Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. Vasc Health Risk Manag 2010;6:1065-75
   PubMedGoogle Scholar
• Grundy SM, Vega GL, McGovern ME, Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-76
   PubMed Web of Science ®Google Scholar
• Younis NN, Soran H, Sharma R, Small-dense LDL and LDL glycation in metabolic syndrome and in statin-treated and non-statin-treated type 2 diabetes. Diab Vasc Dis Res 2010;7:289-95
   PubMed Web of Science ®Google Scholar
• Soran H, Durrington PN. Susceptibility of LDL and its subfractions to glycation. Curr Opin Lipidol 2011;22:254-61
   PubMed Web of Science ®Google Scholar
• Krentz AJ. Lipoprotein abnormalities and their consequences for patients with type 2 diabetes. Diabetes Obes Metab 2003;5(Suppl 1):S19-27
   PubMed Web of Science ®Google Scholar
• Morgan JM, Capuzzi DM, Baksh RI, Effects of extended-release niacin on lipoprotein subclass distribution. Am J Cardiol 2003;91:1432-6
   PubMed Web of Science ®Google Scholar
• Bays HE, Dujovne CA, McGovern ME, Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). Am J Cardiol 2003;91:667-72
   PubMed Web of Science ®Google Scholar
• Erqou S, Kaptoge S, Perry PL, Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23
   PubMed Web of Science ®Google Scholar
• Nordestgaard BG, Chapman MJ, Ray K, Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53
   PubMed Web of Science ®Google Scholar
• Utermann G. Lipoprotein(a). In: Scriver CR, Beaudet AL, editors. The metabolic and molecular bases of inherited disease. McGraw Hill; New York: 2001. p. 2753-87
   Google Scholar
• Koschinsky ML, Marcovina SM. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr Opin Lipidol 2004;15:167-74
   PubMed Web of Science ®Google Scholar
• Maccubbin D, Bays HE, Olsson AG, Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2008;62:1959-70
   PubMed Web of Science ®Google Scholar
• McGovern M. Niaspan: creating a new concept for raising HDL-cholesterol. European Heart Journal Supplements 2005;7:41-7
   Web of Science ®Google Scholar
• Cannon CP, Shah S, Dansky HM, Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15
   PubMed Web of Science ®Google Scholar
• Sacks FM, McPherson R, Walsh BW. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med 1994;154:1106-10
   PubMedGoogle Scholar
• Soma M, Fumagalli R, Paoletti R, Plasma Lp(a) concentration after oestrogen and progestagen in postmenopausal women. Lancet 1991;337:612
   PubMed Web of Science ®Google Scholar
• Canner PL, Berge KG, Wenger NK, Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin. J Am Coll Cardiol 1986;8:1245-55
   PubMed Web of Science ®Google Scholar
• Lee JM, Robson MD, Yu LM, Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study. J Am Coll Cardiol 2009;54:1787-94
   PubMed Web of Science ®Google Scholar
• Brown BG, Brockenbrough A, Zhao X. Very intensive lipid therapy with lovastatin, niacin, and colestipol for prevention of death and myocardial infarction: a 10-year Familial Atherosclerosis Treatment Study (FATS) follow-up [abstract 3341]. Circulation 1998;98:I-635
   Web of Science ®Google Scholar
• The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH). Am Heart J 2011;161:471-7. e2
   PubMed Web of Science ®Google Scholar
• NIH stops clinical trial on combination cholesterol treatment: lack of efficacy in reducing cardiovascular events prompts decision. National Institute of Health News 2011. Available from: http://www.nih.gov/news/health/may2011/nhlbi-26.htm
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes–2010. Diabetes Care 2010;33(Suppl 1):S11-61
   PubMed Web of Science ®Google Scholar
• Singh IM, Shishehbor MH, Ansell BJ. High-density lipoprotein as a therapeutic target: a systematic review. JAMA 2007;298:786-98
   PubMed Web of Science ®Google Scholar
• First ESC/EAS guidelines for dyslipidemia- EAS 2011 Gothenburg, Sweden. 2011. Available from: http://www.eas-society.org/News.aspx?newsId=118 [Cited 7 January 2011]
   Google Scholar
• NICE Clinical Guidelines, No. 66, London. 2008. Available from: http://www.ncbi.nlm.nih.gov/books/NBK53885/
   Google Scholar
• Cooper A, O'Flynn N. Risk assessment and lipid modification for primary and secondary prevention of cardiovascular disease: summary of NICE guidance. BMJ 2008;336:1246-8
   PubMed Web of Science ®Google Scholar
• Bays HE, Shah A, Lin J, Efficacy and tolerability of extended-release niacin/laropiprant in dyslipidemic patients with metabolic syndrome. J Clin Lipidol 2010;4:515-21
   PubMed Web of Science ®Google Scholar
• Gleim G. Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia. Br J Cardiol 2009;16:90-7
   Google Scholar
• Shah S, Ceska R, Gil-Extremera B, Efficacy and safety of extended-release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia. Int J Clin Pract 2010;64:727-38
   PubMed Web of Science ®Google Scholar
• Maclean A. Efficacy and safety of extended-release niacin/laropiprant in patients with type 2 diabetes mellitus. Br J Cardiol 2011;18:37-45
   Google Scholar
• Guyton JR, Bays HE. Safety considerations with niacin therapy. Am J Cardiol 2007;99:22C-31C
   PubMed Web of Science ®Google Scholar
• Tato F, Vega GL, Grundy SM. Effects of crystalline nicotinic acid-induced hepatic dysfunction on serum low-density lipoprotein cholesterol and lecithin cholesteryl acyl transferase. Am J Cardiol 1998;81:805-7
   PubMed Web of Science ®Google Scholar
• Vaccari CS, Hammoud RA, Nagamia SH, Revisiting niacin: reviewing the evidence. J Clin Lipidol 2007;1:248-55
   PubMed Web of Science ®Google Scholar
• Bays HE, McGovern ME. Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin. Prev Cardiol 2003;6:179-88
   PubMedGoogle Scholar
• Durrington P. Hyperlipidaemia diagnosis and management. 3rd edition. Hodder Arnold; London: 2007
   Google Scholar
• K/DOQI Clinical Practice Guidelines for Managing Dyslipidemias in Chronic Kidney Disease. American Journal of Kidney Diseases 2003;41:Suppl 3
   Google Scholar
• Increased myopathy with combination use of ER niacin/laropiprant (Tredaptive®) and simvastatin 40 mg in Chinese patients. Results from interim analysis of HPS2-THRIVE study. Safety alerts 2010. Available from: http://www.hsa.gov.sg/publish/hsaportal/en/health_products_regulation/safety_information/product_safety_alerts/safety_alerts_2010/increased_myopathy.html
   Google Scholar
• Carlson LA. Studies on the effect of nicotinic acid on catecholamine stimulated lipolysis in adipose tissue in vitro. Acta Med Scand 1963;173:719-22
   PubMed Web of Science ®Google Scholar
• Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000;106:171-6
   PubMed Web of Science ®Google Scholar
• Durrington PN. Hyperlipidaemia: diagnosis and management. Hodder Arnold; London: 2007
   Google Scholar
• Schwartz ML. Severe reversible hyperglycemia as a consequence of niacin therapy. Arch Intern Med 1993;153:2050-2
   PubMed Web of Science ®Google Scholar
• McCulloch DK, Kahn SE, Schwartz MW, Effect of nicotinic acid-induced insulin resistance on pancreatic B cell function in normal and streptozocin-treated baboons. J Clin Invest 1991;87:1395-401
   PubMed Web of Science ®Google Scholar
• Canner PL, Furberg CD, Terrin ML, Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project). Am J Cardiol 2005;95:254-7
   PubMed Web of Science ®Google Scholar
• Sampathkumar K, Selvam M, Sooraj YS, Extended release nicotinic acid - a novel oral agent for phosphate control. Int Urol Nephrol 2006;38:171-4
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Tanaka A, Nakamura T, Nicotinamide suppresses hyperphosphatemia in hemodialysis patients. Kidney Int 2004;65:1099-104
   PubMed Web of Science ®Google Scholar
• Birjmohun RS, Hutten BA, Kastelein JJ, Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005;45:185-97
   PubMed Web of Science ®Google Scholar
• Paolini JF, Mitchel YB, Reyes R, Effects of laropiprant on nicotinic acid-induced flushing in patients with dyslipidemia. Am J Cardiol 2008;101:625-30
   PubMed Web of Science ®Google Scholar
• McKenney J. Safety profile of extended release niacin/laropiprant in patients with dyslipidemia. J Am Coll Cardiol 2008;51:334
   Web of Science ®Google Scholar
• Lauring B, Dishy V, Luo WL, Laropiprant in combination with extended-release niacin does not alter urine 11-dehydrothromboxane B2, a marker of in vivo platelet function, in healthy, hypercholesterolemic, and diabetic subjects. J Clin Pharmacol 2009;49:1426-35
   PubMed Web of Science ®Google Scholar
• Dishy V, Liu F, Ebel DL, Effects of aspirin when added to the prostaglandin D2 receptor antagonist laropiprant on niacin-induced flushing symptoms. J Clin Pharmacol 2009;49:416-22
   PubMed Web of Science ®Google Scholar
• Soran H, France MW, Kwok S, Apolipoprotein B100 is a better treatment target than calculated LDL and non-HDL cholesterol in statin-treated patients. Ann Clin Biochem 2011;48:566-71
   PubMed Web of Science ®Google Scholar
• Keech A, Simes RJ, Barter P, Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005;366:1849-61
   PubMed Web of Science ®Google Scholar
• Tonkin AM, Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Circulation 2010;122:850-2
   PubMed Web of Science ®Google Scholar
• Mymin D, Dembinski T, Friesen MH. Iatrogenic severe depression of high-density lipoprotein cholesterol. J Clin Pharmacol 2009;49:865-71
   PubMedGoogle Scholar
• Fayad ZA, Mani V, Woodward M, Safety and efficacy of dalcetrapib on atherosclerotic disease using novel non-invasive multimodality imaging (dal-PLAQUE): a randomised clinical trial. Lancet 2011;378:1547-59
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Brewer HB, Kastelein JJ, Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial. JAMA 2011;306:2099-109
   PubMed Web of Science ®Google Scholar
• Blankenhorn DH, Nessim SA, Johnson RL, Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40
   PubMed Web of Science ®Google Scholar
• Kane JP, Malloy MJ, Ports TA, Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 1990;264:3007-12
   PubMed Web of Science ®Google Scholar